Back to top

earnings-consensus: Archive

Zacks Equity Research

Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?

Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INOPositive Net Change VTGNPositive Net Change

Zacks Equity Research

Bitfarms Ltd. (BITF) Expected to Beat Earnings Estimates: Should You Buy?

Bitfarms (BITF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BITFPositive Net Change JAMFPositive Net Change

Zacks Equity Research

Earnings Preview: Cava Group (CAVA) Q2 Earnings Expected to Decline

Cava (CAVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAVANegative Net Change QSRPositive Net Change

Zacks Equity Research

Lumentum (LITE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Lumentum (LITE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LITEPositive Net Change ATUSNegative Net Change

Zacks Equity Research

XP Inc.A (XP) to Report Q2 Results: Wall Street Expects Earnings Growth

XP Inc.A (XP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

XPNegative Net Change HASINegative Net Change

Zacks Equity Research

Earnings Preview: Eagle Point (ECC) Q2 Earnings Expected to Decline

Eagle Point (ECC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ECCPositive Net Change VCTRNegative Net Change

Zacks Equity Research

Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

FOLDPositive Net Change

Zacks Equity Research

Wall Street Analysts Think Ezcorp (EZPW) Could Surge 42.47%: Read This Before Placing a Bet

The mean of analysts' price targets for Ezcorp (EZPW) points to a 42.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

EZPWNegative Net Change

Zacks Equity Research

Wall Street Analysts Think Perrigo (PRGO) Could Surge 36.02%: Read This Before Placing a Bet

The mean of analysts' price targets for Perrigo (PRGO) points to a 36% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

PRGOPositive Net Change

Zacks Equity Research

Wall Street Analysts Predict a 31.21% Upside in Precision Drilling (PDS): Here's What You Should Know

The mean of analysts' price targets for Precision Drilling (PDS) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

PDSPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade

The consensus price target hints at a 695.5% upside potential for IMAGENEBIO INC (IMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

IMAPositive Net Change

Zacks Equity Research

How Much Upside is Left in Forge Global (FRGE)? Wall Street Analysts Think 46.09%

The average of price targets set by Wall Street analysts indicates a potential upside of 46.1% in Forge Global (FRGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

FRGENegative Net Change

Zacks Equity Research

Monday.com (MNDY) Expected to Beat Earnings Estimates: Should You Buy?

Monday.com (MNDY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MNDYPositive Net Change STNENegative Net Change

Zacks Equity Research

Analysts Estimate Mercury Systems (MRCY) to Report a Decline in Earnings: What to Look Out for

Mercury Systems (MRCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRCYPositive Net Change CWPositive Net Change

Zacks Equity Research

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TSHANegative Net Change AMPHNegative Net Change

Zacks Equity Research

Exodus Movement, Inc. (EXOD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Exodus Movement, Inc. (EXOD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EXODNegative Net Change GRNDPositive Net Change

Zacks Equity Research

Will Gevo, Inc. (GEVO) Report Negative Earnings Next Week? What You Should Know

Gevo (GEVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GEVONegative Net Change ORAPositive Net Change

Zacks Equity Research

Will HIVE Digital Technologies (HIVE) Report Negative Q1 Earnings? What You Should Know

HIVE Digital Technologies (HIVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HIVEPositive Net Change STEPNegative Net Change

Zacks Equity Research

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HROWNegative Net Change ACRSNegative Net Change

Zacks Equity Research

Earnings Preview: Kolibri Global Energy Inc. (KGEI) Q2 Earnings Expected to Decline

Kolibri Global Energy Inc. (KGEI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

KGEINegative Net Change TLNNegative Net Change

Zacks Equity Research

ACV Auctions Inc. (ACVA) Reports Next Week: Wall Street Expects Earnings Growth

ACV Auctions (ACVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACVANegative Net Change

Zacks Equity Research

Aris Water Solutions, Inc. (ARIS) Earnings Expected to Grow: Should You Buy?

Aris Water Solutions (ARIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ARISNegative Net Change MEGNegative Net Change

Zacks Equity Research

Bitdeer Technologies Group (BTDR) Expected to Beat Earnings Estimates: Should You Buy?

BITDEER TEC GRP (BTDR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BTDRPositive Net Change AMPXPositive Net Change

Zacks Equity Research

Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Journey Medical (DERM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DERMPositive Net Change NKTRPositive Net Change

Zacks Equity Research

Earnings Preview: Ellington Credit (EARN) Q2 Earnings Expected to Decline

Ellington Credit (EARN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EARNNegative Net Change RCNegative Net Change